In a filing, Actuate Therapeutics Inc revealed its Director Bios Equity COF, LP acquired Company’s shares for reported $0.5 million on Jun 27 ’25. In the deal valued at $7.00 per share,71,428 shares were bought. As a result of this transaction, Bios Equity COF, LP now holds 196,428 shares worth roughly $1.2 million.
Then, Kreis Leslie W. bought 71,428 shares, generating $499,996 in total proceeds. Upon buying the shares at $7.00, the Director now owns 196,428 shares.
Before that, Fletcher Aaron G.L. bought 71,428 shares. Actuate Therapeutics Inc shares valued at $499,996 were divested by the Director at a price of $7.00 per share. As a result of the transaction, Fletcher Aaron G.L. now holds 196,428 shares, worth roughly $1.2 million.
Craig Hallum initiated its Actuate Therapeutics Inc [ACTU] rating to a Buy in a research note published on April 22, 2025; the price target was $21. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating.
Price Performance Review of ACTU
On Tuesday, Actuate Therapeutics Inc [NASDAQ:ACTU] saw its stock jump 0.33% to $6.13. Over the last five days, the stock has lost -9.19%. Nevertheless, the stocks have fallen -22.99% over the past one year.
Levels Of Support And Resistance For ACTU Stock
The 24-hour chart illustrates a support level at 5.82, which if violated will result in even more drops to 5.52. On the upside, there is a resistance level at 6.41. A further resistance level may holdings at 6.70.
How much short interest is there in Actuate Therapeutics Inc?
A steep rise in short interest was recorded in Actuate Therapeutics Inc stocks on 2025-06-13, growing by 43087.0 shares to a total of 0.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 0.2 million shares. There was a rise of 17.85%, which implies that there is a positive sentiment for the stock.
